Cargando…

Correction: Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031218/ http://dx.doi.org/10.1371/journal.pone.0098836

Ejemplares similares

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
por: Guren, Tormod Kyrre, et al.
Publicado: (2017)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Correction: Increased Plasma YKL-40/Chitinase-3-Like-Protein-1 Is Associated with Endothelial Dysfunction in Obstructive Sleep Apnea
Publicado: (2014)

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
por: Zekri, Jamal, et al.
Publicado: (2022)

Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2018)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Serum YKL-40 Levels Are Associated with the Atherogenic Index of Plasma in Children
por: Kwon, Yoowon, et al.
Publicado: (2020)

Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer
por: Oh, Il Hwan, et al.
Publicado: (2021)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Narvi, Elli, et al.
Publicado: (2018)

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)

Upregulation of YKL-40 Promotes Metastatic Phenotype and Correlates with Poor Prognosis and Therapy Response in Patients with Colorectal Cancer
por: De Robertis, Mariangela, et al.
Publicado: (2022)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
por: Hashimoto, Akari, et al.
Publicado: (2014)

Correction: Expression of the Chitinase Family Glycoprotein YKL-40 in Undifferentiated, Differentiated and Trans-Differentiated Mesenchymal Stem Cells
Publicado: (2014)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
por: Zhang, Zhan-Dong, et al.
Publicado: (2014)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
por: Pander, Jan, et al.
Publicado: (2015)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Correction for: YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
por: Andrés‐Benito, Pol, et al.
Publicado: (2021)

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
por: Kullmann, F, et al.
Publicado: (2009)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
por: Nielsen, Anders R., et al.
Publicado: (2008)

Usefulness of Plasma YKL-40 in Management of Community-Acquired Pneumonia Severity in Patients
por: Wang, Hsiang-Ling, et al.
Publicado: (2013)

Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD
por: Wang, Jing, et al.
Publicado: (2018)

Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis
por: Wang, Jian, et al.
Publicado: (2022)

Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer
por: Santoro, Valeria, et al.
Publicado: (2015)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients
por: Dai, Xichao, et al.
Publicado: (2016)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2022)

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease
por: Holmgaard, Dennis B, et al.
Publicado: (2013)

Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease
por: KESKİN, Gül Sema, et al.
Publicado: (2019)

Elevated plasma YKL-40 level is found in the dogs with cancer and is related to poor prognosis
por: Cheng, Kai-Chung, et al.
Publicado: (2019)

Plasma levels of YKL-40 as a prognostic factor in childhood acute lymphoblastic leukemia
por: Rivas-Alarcón, Alinne Ayulieth, et al.
Publicado: (2021)

YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
por: Rathcke, Camilla N, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ea04a8u9hlm5clrili94m5hm6u